Riskpilot← Back to searchSign inGet full accessOvodan Biotech A/S
A/SActiveCVR 33870256Havnegade 36Research and experimental development on natural sciences and engineering · NACE 7210Est. 2011— employees
Revenue 2024
DKK -313K
+99% vs 2023
EBITDA margin
290.8%
-47% vs 2023
Equity ratio
21.8%
Financial strength
Net profit 2024
DKK -1,2M
-633% vs 2023
| Revenue | DKK -313K | +99% |
| EBITDA | DKK -909K | -47% |
| Net profit | DKK -1,2M | -633% |
| Total assets | DKK 1,4M | -20% |
| Equity | DKK 316K | +102% |
| Employees | — | — |
Legal name
Ovodan Biotech A/S
CVR number
33870256
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. juli 2011
Share capital
DKK 1.000.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af Thor Stadil alene, af Christian Nicholas Stadil alene eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning, produktion og salg af enheder indenfor det biotekniske område og anden dermed i forbindelse stående virksomhed.
Address
Havnegade 36
Phone
+4566111732
Email
mki@sanovo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -515 | -192 | 16 | 1.349 | -286 | -272 | -720 | -1.780 | -1.527 | -741 | -439 | -157 | -313 |
| Staff expenses | -1.118 | -989 | -1.998 | -2.100 | -1.652 | -1.843 | -1.988 | -1.550 | -2.137 | -1.289 | -925 | -463 | -596 |
| EBITDA | -1.633 | -1.181 | -1.982 | -751 | -1.937 | -2.115 | -2.708 | -3.330 | -3.663 | -2.030 | -1.364 | -620 | -909 |
| Depreciation & amort. | -0 | -1 | -29 | -107 | -222 | -251 | -251 | -249 | -244 | -210 | -137 | -96 | -87 |
| EBIT | -1.633 | -1.181 | -2.011 | -858 | -2.159 | -2.366 | -2.959 | -3.579 | -3.907 | -2.240 | -1.501 | -716 | -996 |
| Net financials | 2 | -1 | -313 | -580 | -706 | -232 | -272 | -330 | -371 | -399 | -461 | 560 | -431 |
| Profit before tax | -1.630 | -1.182 | -2.324 | -1.438 | -2.865 | -2.598 | -3.231 | -3.909 | -4.279 | -2.639 | -1.963 | -156 | -1.427 |
| Tax | -406 | -309 | -580 | -364 | -658 | -216 | -589 | -975 | -1.137 | -665 | -432 | -377 | -250 |
| Net profit | -1.224 | -873 | -1.744 | -1.073 | -2.208 | -2.383 | -2.641 | -2.934 | -3.142 | -1.973 | -1.531 | 221 | -1.178 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 657 | 1.457 | 3.740 | 5.365 | 4.212 | 4.617 | 4.213 | 3.415 | 2.676 | 1.971 | 1.787 | 1.815 | 1.449 |
| Equity | -224 | -1.097 | -2.841 | -3.914 | -6.122 | -8.505 | -11.146 | -14.081 | -17.222 | -19.196 | -20.727 | -20.506 | 316 |
| Long-term debt | 0 | 0 | 0 | 8.616 | 10.174 | 13.003 | 15.057 | 17.455 | 19.415 | 20.854 | 22.369 | 22.281 | 1.112 |
| Short-term debt | 881 | 2.554 | 6.547 | 565 | 35 | 49 | 288 | 40 | 484 | 312 | 145 | 40 | 20 |
| Total debt | 881 | 2.554 | 6.547 | 9.180 | 10.209 | 13.053 | 15.345 | 17.496 | 19.899 | 21.166 | 22.513 | 22.321 | 1.132 |
EBITDA margin
-90902000.0%
This company
15.8%
Market median
-575329214% vs market
20122024
Equity ratio
21.8%
This company
38.2%
Market median
-43% vs market
20122024
Return on equity
-372.1%
This company
18.4%
Market median
-2122% vs market
20122024
Net profit margin
-117765100.0%
This company
8.1%
Market median
-1453890223% vs market
20122024
Asset turnover
-0.22×
This company
1.12×
Market median
-120% vs market
20122024
Debt / equity
3.58×
This company
0.62×
Market median
-477% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-07-20 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HM Management | Management | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2011 | — | — | |
| Chairman | 2011 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ovodan Foods A/S | Company | 100.0% | 100.0% | 2024 |
Ovodan Europe A/S | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Thornico Food & Food Technology Group A/SOvodan Europe A/SOvodan Foods A/S
Ovodan Biotech A/S (this company)Board members of Ovodan Biotech A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Marinus Pedersen | Management | 0 companies |
| Christian Nicholas Rosenkrantz Stadil | Board of Directors | 0 companies |
| Jørn Leth Frandsen | Board of Directors | 0 companies |
| Thor Stadil | Chairman | 0 companies |